A review of antipsychotic agents in late-stage development (August 2005).
How Magellan’s Behavior Health Program Saved up to $4,300 PMPY
Using an AI platform, Magellan Health was able to better support providers in prescribing behavioral health medications and addressing medication problems, which reduced pharmacy costs and increased adherence.
FDA Approves Extended-Release Therapy for Major Depression
Exxua is approved to treat adults with major depressive disorder, but its labeling does not contain warnings about sexual function or weight gain.
FDA Accepts NDA for Zuranolone for Depression
Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.
FDA Approves Vraylar for Major Depressive Disorder
This is the fourth indication for Vraylar, a dopamine and serotonin partial agonist that can now be used as an adjunctive therapy in patients with major depressive disorder.
EmpiRx Health Lowers Drug Spend in Mental Health
EmpiRx Health CEO Karthik Ganesh discusses how the PBM was able to decrease mental health drug spending at a time when utilization is increasing.
FDA Accepts NDA for Longer-Acting Aripiprazole
Aripiprazole, currently available as a once-monthly injection under the brand name Abilify Maintena, is being reviewed as a two-month therapy. The FDA target date for completion of the review is April 27, 2023.
2 Clarke Drive Cranbury, NJ 08512